» Articles » PMID: 33208342

Cobomarsen, an Oligonucleotide Inhibitor of MiR-155, Slows DLBCL Tumor Cell Growth and

Abstract

Purpose: miRNA-155 is an oncogenic miRNA highly expressed in B-cell malignancies, particularly in the non-germinal center B-cell or activated B-cell subtype of diffuse large B-cell lymphoma (ABC-DLBCL), where it is considered a potential diagnostic and prognostic biomarker. Thus, miR-155 inhibition represents an important therapeutic strategy for B-cell lymphomas. In this study, we tested the efficacy and pharmacodynamic activity of an oligonucleotide inhibitor of miR-155, cobomarsen, in ABC-DLBCL cell lines and in corresponding xenograft mouse models. In addition, we assessed the therapeutic efficacy and safety of cobomarsen in a patient diagnosed with aggressive ABC-DLBCL.

Experimental Design: Preclinical studies included the delivery of cobomarsen to highly miR-155-expressing ABC-DLBCL cell lines to assess any phenotypic changes, as well as intravenous injections of cobomarsen in NSG mice carrying ABC-DLBCL xenografts, to study tumor growth and pharmacodynamics of the compound over time. To begin to test its safety and therapeutic efficacy, a patient was recruited who underwent five cycles of cobomarsen treatment.

Results: Cobomarsen decreased cell proliferation and induced apoptosis in ABC-DLBCL cell lines. Intravenous administration of cobomarsen in a xenograft NSG mouse model of ABC-DLBCL reduced tumor volume, triggered apoptosis, and derepressed direct miR-155 target genes. Finally, the compound reduced and stabilized tumor growth without any toxic effects for the patient.

Conclusions: Our findings support the potential therapeutic application of cobomarsen in ABC-DLBCL and other types of lymphoma with elevated miR-155 expression.

Citing Articles

Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.

Liu M, Wang Y, Zhang Y, Hu D, Tang L, Zhou B Signal Transduct Target Ther. 2025; 10(1):73.

PMID: 40059188 PMC: 11891339. DOI: 10.1038/s41392-024-02112-8.


The Role of microRNA-155 as a Biomarker in Diffuse Large B-Cell Lymphoma.

Koumpis E, Georgoulis V, Papathanasiou K, Papoudou-Bai A, Kanavaros P, Kolettas E Biomedicines. 2025; 12(12.

PMID: 39767565 PMC: 11673977. DOI: 10.3390/biomedicines12122658.


The role of miR-155 in cardiovascular diseases: Potential diagnostic and therapeutic targets.

Zhang R, Wang W, Li J, Li R, Zhang J, Wu Y Int J Cardiol Cardiovasc Risk Prev. 2025; 24:200355.

PMID: 39760132 PMC: 11699627. DOI: 10.1016/j.ijcrp.2024.200355.


Advances in epigenetic therapies for B-cell non-hodgkin lymphoma.

Hu W, Zang L, Feng X, Zhuang S, Chang L, Liu Y Ann Hematol. 2024; 103(12):5085-5101.

PMID: 39652169 DOI: 10.1007/s00277-024-06131-x.


The role of miR-152 in urological tumors: potential biomarkers and therapeutic targets.

Li X, Qian B, Chen X, Shen M, Zhao S, Zhang X Front Immunol. 2024; 15:1464327.

PMID: 39606232 PMC: 11599204. DOI: 10.3389/fimmu.2024.1464327.


References
1.
Rupaimoole R, Slack F . MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017; 16(3):203-222. DOI: 10.1038/nrd.2016.246. View

2.
Anastasiadou E, Stroopinsky D, Alimperti S, Jiao A, Pyzer A, Cippitelli C . Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas. Leukemia. 2018; 33(1):132-147. PMC: 6327052. DOI: 10.1038/s41375-018-0178-x. View

3.
Kaczmarek J, Kowalski P, Anderson D . Advances in the delivery of RNA therapeutics: from concept to clinical reality. Genome Med. 2017; 9(1):60. PMC: 5485616. DOI: 10.1186/s13073-017-0450-0. View

4.
Babar I, Cheng C, Booth C, Liang X, Weidhaas J, Saltzman W . Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma. Proc Natl Acad Sci U S A. 2012; 109(26):E1695-704. PMC: 3387084. DOI: 10.1073/pnas.1201516109. View

5.
Jiang S, Zhang H, Lu M, He X, Li Y, Gu H . MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res. 2010; 70(8):3119-27. DOI: 10.1158/0008-5472.CAN-09-4250. View